COVID-19 New Cases 488... 4 Consecutive Days in the 400s

The Seoul National University Hospital's in-house COVID-19 vaccination took place on the morning of the 4th at Seoul National University Hospital in Daehak-ro, Jongno-gu, Seoul. Kim Yeon-su, the director of Seoul National University Hospital, is receiving the AstraZeneca vaccine. 2021.03.04

[Asia Economy Reporter Lee Chun-hee] The daily number of new COVID-19 cases in South Korea has remained in the 400s for four consecutive days.

The Korea Disease Control and Prevention Agency (KDCA) Central Disease Control Headquarters announced on the 12th that as of midnight, the total number of confirmed COVID-19 cases increased by 488 from the previous day to 94,686.

The sources of infection for the new confirmed cases were 467 local transmissions and 21 imported cases.

About 70% of the locally transmitted cases occurred in the Seoul metropolitan area. There were 138 cases in Seoul (29.6%), 157 in Gyeonggi (33.6%), and 29 in Incheon (6.2%), totaling 324 cases in the metropolitan area, accounting for 69.4% of all confirmed cases.

Other regions reported new cases as follows: 56 in Gyeongnam, 27 in Chungbuk, 14 in Busan, 12 in Gangwon, 9 in Gyeongbuk, 4 each in Daegu, Ulsan, Jeonbuk, and Jeonnam, 3 in Chungnam, 2 each in Gwangju, Sejong, and Jeju. Daejeon reported no new cases.

There were 21 imported cases. Among them, 6 were detected during quarantine, and 15 were confirmed in the community. Nine were Korean nationals and 12 were foreigners.

The number of patients who have recovered and been released from isolation reached 85,743, an increase of 1,068 from the previous day. Among hospitalized patients, the number of critically ill patients remained unchanged at 127. The death toll rose by 10 to 1,662.

A total of 64,065 tests were conducted the previous day. At temporary screening clinics set up in the metropolitan area, 28,386 tests were performed, confirming 75 new cases.

Meanwhile, as of midnight, 42,527 additional people received COVID-19 vaccinations, bringing the total number of first-dose recipients to 546,277. Among them, 526,414 received the AstraZeneca vaccine, and 19,863 received the Pfizer vaccine.

There were 789 new reports of suspected adverse reactions, bringing the total to 7,648. Of the new reports, 785 were mild symptoms such as headache, fever, nausea, and vomiting, while 4 were suspected cases of anaphylaxis.

This content was produced with the assistance of AI translation services.